title: Rapid diagnostic HCV antibody assays.
abstract: Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection. Performance characteristics of pre-market rapid anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9-99.3%) and specificity (80-100%) varied. Future investigations could include evaluation of rapid anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-antigen tests and nucleic acid tests.
authors: Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA. bli1@cdc.gov
authors: Bryce D
authors: BD
authors: Smith
authors: Amy
authors: A
authors: Jewett
authors: Jan
authors: J
authors: Drobeniuc
authors: Saleem
authors: S
authors: Kamili
mesh_terms: D016174:Hepacivirus / Q000276:immunology* / Q000302:isolation & purification; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood*; D018936:Hepatitis C Antigens / Q000276:immunology; D006801:Humans; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D013997:Time Factors; D014481:United States / Q000453:epidemiology
chemical_list: D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens; D011933:Reagent Kits, Diagnostic